<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="other"><?properties open_access?><!-- Original-type: cl--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">12865911</article-id><article-id pub-id-type="pmc">2394263</article-id><article-id pub-id-type="pii">6601043</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6601043</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical</subject></subj-group></article-categories><title-group><article-title>Phase 1 study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Newlands</surname><given-names>E S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Foster</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zaknoen</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label><sup>1</sup>Imperial College School of Medicine, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK</aff><aff id="aff2"><label>2</label><sup>2</sup>Schering-Plough Research Institute K-15-3-3200, 2015 Galloping Hill Rd, Kenilworth, NJ 07033, USA</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:e.newlands@ic.ac.uk">e.newlands@ic.ac.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>07</month><year>2003</year></pub-date><pub-date pub-type="ppub"><day>21</day><month>07</month><year>2003</year></pub-date><volume>89</volume><issue>2</issue><fpage>248</fpage><lpage>251</lpage><history><date date-type="received"><day>25</day><month>10</month><year>2002</year></date><date date-type="rev-recd"><day>15</day><month>04</month><year>2003</year></date><date date-type="accepted"><day>22</day><month>04</month><year>2003</year></date></history><copyright-statement>Copyright 2003, Cancer Research UK</copyright-statement><copyright-year>2003</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><kwd-group><kwd>temozolamide</kwd><kwd>procarbazine</kwd><kwd>glioma</kwd></kwd-group></article-meta></front><body><p>Prognosis with patients with glioma, and in particular, high-grade (anaplastic astrocytoma (AA) and glioblastoma multiforme (GBM)) tumours is poor. Studies have confirmed the beneficial effect of postoperative cranial irradiation, but in most series, survival beyond 2 years is 15&#x00025; or less (<xref ref-type="other" rid="bib19">Walker <italic>et al</italic>, 1978</xref>; <xref ref-type="other" rid="bib16">Stewart, 1989</xref>; <xref ref-type="other" rid="bib4">Fine <italic>et al</italic>, 1993</xref>). The most widely used combination in treating gliomas is procarbazine, CCNU (lomustine), vincristine (PCV). This has a limited effect on survival (<xref ref-type="other" rid="bib6">Levin <italic>et al</italic>, 1980</xref>; <xref ref-type="other" rid="bib11">Sandberg-Wollheim <italic>et al</italic>, 1991</xref>). The most active agents identified until recently were the nitrosoureas (BCNU, CCNU, methyl-CCNU and HECNU), and have been reported to induce responses in the range of 35&#x02013;55&#x00025;. However, the majority of these responses were of short duration (<xref ref-type="other" rid="bib9">Rodriguez and Levin, 1987</xref>; <xref ref-type="other" rid="bib5">Georges <italic>et al</italic>, 1988</xref>; Stewart, 1989).</p><p>Temozolomide came from a synthetic programme of a number of imidazotetrazine derivatives, which exhibited broad-spectrum antitumour activity against murine models (<xref ref-type="other" rid="bib15">Stevens <italic>et al</italic>, 1984</xref>). TMZ was selected for further clinical development in view of its good experimental antitumour activity and low toxicity in the pre-clinical screen. In addition, its antitumour activity was also schedule-dependent (<xref ref-type="other" rid="bib14">Stevens <italic>et al</italic>, 1987</xref>). In the early clinical development of TMZ, administration of a single dose induced myelosupression but did not have any antitumour activity. However, when given on a daily 5 &#x000d7; schedule repeated every 4 weeks, activity against malignant melanomas and gliomas was seen (<xref ref-type="other" rid="bib8">Newlands <italic>et al</italic>, 1992</xref>). TMZ spontaneously ring opens at physiological pH to produce the active intermediate MTIC, which methylates DNA at a number of sites. The main cytotoxic lesion induced by TMZ is probably at the <italic>O</italic><sup>6</sup> position of guanine (<xref ref-type="other" rid="bib17">Tisdale, 1987</xref>; <xref ref-type="other" rid="bib1">Baer <italic>et al</italic>, 1993</xref>; <xref ref-type="other" rid="bib20">Wedge <italic>et al</italic>, 1996</xref>). This cytotoxic lesion is repaired by the DNA-repair protein O<sup>6</sup>-alkylguanine DNA alkyltransferase (AGT) that accepts the methyl group onto a cysteine residue and is autoinactivated. TMZ, especially administered in repeat dosing, will deplete tumour cells of AGT (<xref ref-type="other" rid="bib3">D'Incalci <italic>et al</italic>, 1991</xref>; <xref ref-type="other" rid="bib7">Mitchell and Dolan, 1993</xref>).</p><p>PCB has been used as an oral agent for many years in patients with malignant lymphomas (MOPP (mustine, vincristine, procarbazine, and prednisolone)) and in PCV-treated malignant gliomas. A number of studies in the 1990s also identified that procarbazine, a DNA-alkylating agent, depletes AGT (<xref ref-type="other" rid="bib12">Schold <italic>et al</italic>, 1989</xref>; <xref ref-type="other" rid="bib13">Souliotis <italic>et al</italic>, 1990</xref>; <xref ref-type="other" rid="bib18">Valvanis <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib10">Russell <italic>et al</italic>, 1995</xref>). This study was designed to identify whether there is potentially an increase in the therapeutic index by combining PCB and TMZ in treating patients with malignant gliomas.</p><sec sec-type="methods"><title>PATIENTS AND METHODS</title><p>Following ethics committee approval, 28 patients with malignant gliomas were enrolled in this study and their details are shown in <xref rid="tbl1" ref-type="table">Table 1</xref>
 <table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Clinical structure: temozolomide and procarbazine phase I</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/></colgroup><tbody valign="top"><tr><td align="left" valign="top" charoff="50"><bold>Clinical details</bold><hr/></td><td align="center" valign="top" charoff="50"><bold>Numbers</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">Gender</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Male</td><td align="char" valign="top" char="." charoff="50">17</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Female</td><td align="char" valign="top" char="." charoff="50">11</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Age</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median</td><td align="char" valign="top" char="." charoff="50">47</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Range</td><td align="char" valign="top" char="." charoff="50">18&#x02013;67</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Diagnosis</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Glioma</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Glioma Grade 2</td><td align="char" valign="top" char="." charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Glioma Grade 3</td><td align="char" valign="top" char="." charoff="50">7</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Glioma Grade 4</td><td align="char" valign="top" char="." charoff="50">16</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Oligodenroglioma</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Grade 2</td><td align="char" valign="top" char="." charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Oligodenroglioma&#x02013;Astrocytoma</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Grade 2</td><td align="char" valign="top" char="." charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50">Total entered</td><td align="char" valign="top" char="." charoff="50">28</td></tr></tbody></table></table-wrap>. All had received prior surgery and radiotherapy, and none had received chemotherapy and all had progressive disease. The study design was such that TMZ alone was administered during course 1 to determine whether or not each patient's bone marrow was sensitive to TMZ at full dose. The second and subsequent courses of TMZ were combined with escalating doses of PCB (<xref rid="tbl2" ref-type="table">Table 2</xref>
 <table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Study design: temozolomide and procarbazine phase I</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/><col align="left"/></colgroup><tbody valign="top"><tr><td align="left" valign="top" charoff="50">&#x000a0;<hr/></td><td align="left" valign="top" charoff="50"><bold>Course</bold><hr/></td><td align="left" valign="top" charoff="50"><bold>Period</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50"><italic>Course 1</italic></td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Temozolomide 200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup></td><td align="left" valign="top" charoff="50">Days 1&#x02013;5 q 28 days</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Course 2</italic></td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Dose</td><td align="left" valign="top" charoff="50">Subsequent courses:</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Level 1</td><td align="left" valign="top" charoff="50">Procarbazine 50&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup> 1&#x02009;h</td><td align="left" valign="top" charoff="50">Days 1&#x02013;5 q 28 days</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Before temozolomide 200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup></td><td align="left" valign="top" charoff="50">Days 1&#x02013;5</td></tr><tr><td align="left" valign="top" charoff="50">Dose</td><td align="left" valign="top" charoff="50">Subsequent courses:</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Level 2</td><td align="left" valign="top" charoff="50">Procarbazine 75&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup> 1&#x02009;h</td><td align="left" valign="top" charoff="50">Days 1&#x02013;5 q 28 days</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Before temozolomide 200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup></td><td align="left" valign="top" charoff="50">Days 1&#x02013;5</td></tr><tr><td align="left" valign="top" charoff="50">Dose</td><td align="left" valign="top" charoff="50">Subsequent courses:</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Level 3</td><td align="left" valign="top" charoff="50">Procarbazine 100&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup> 1&#x02009;h</td><td align="left" valign="top" charoff="50">Days 1&#x02013;5 q 28 days</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Before temozolomide 200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup></td><td align="left" valign="top" charoff="50">Days 1&#x02013;5</td></tr><tr><td align="left" valign="top" charoff="50">Dose</td><td align="left" valign="top" charoff="50">Subsequent courses:</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Level 4</td><td align="left" valign="top" charoff="50">Procarbazine 125&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup> 1&#x02009;h</td><td align="left" valign="top" charoff="50">Days 1&#x02013;5 q 28 days</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Before temozolomide 200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup></td><td align="left" valign="top" charoff="50">Days 1&#x02013;5</td></tr></tbody></table></table-wrap>). If a patient's bone marrow was sensitive to TMZ at a dose of 200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> daily 5 &#x000d7; , this was reduced in the second course to 150&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> daily 5 &#x000d7; , and then subsequent courses combined with PCB and the reduced dose of TMZ. Patients continued on 4 weekly courses of TMZ at the same dose of PCB until disease progression or evidence of major toxicity.</p><p>Responses were assessed clinically and radiologically before and after each course of treatment. Patients with gliomas had to be taking a stable dose of corticosteroid for at least 2 weeks before study entry and the baseline CT or MRI scan. Radiological shrinkage alone was not considered an acceptable measure of response in brain tumours, as there is often difficulty in forming clear margins on a CT or MRI abnormality, which includes additional areas of necrosis, oedema, and vascularity. In some cases, it may be possible to measure a clearcut reduction of 50&#x00025; by CT or MRI, but in most cases it is only possible to determine a reduction in enhancement and mass effect. An objective response (OR) was defined as one that requires improvement in the Medical Research Council neurological status (<xref rid="tbl3" ref-type="table">Table 3</xref>
 <table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p content-type="table-title">Medical Research Council Neurological Status</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/></colgroup><tbody valign="top"><tr><td align="left" valign="top" charoff="50">0</td><td align="left" valign="top" charoff="50">No neurological deficit</td></tr><tr><td align="left" valign="top" charoff="50">1</td><td align="left" valign="top" charoff="50">Some neurological deficit, but function adequate for useful work</td></tr><tr><td align="left" valign="top" charoff="50">2</td><td align="left" valign="top" charoff="50">Neurological deficit causing moderate functional impairment (e.g. being able to move limb(s)) only with difficulty, moderate dysphasia, moderate paresis, and some visual disturbances (e.g. visual field defect)</td></tr><tr><td align="left" valign="top" charoff="50">3</td><td align="left" valign="top" charoff="50">Neurological deficit causing major functional impairment for example inability to move limbs, gross speech, or visual disturbance</td></tr><tr><td align="left" valign="top" charoff="50">4</td><td align="left" valign="top" charoff="50">No useful function; inability to make conscious responses</td></tr></tbody></table></table-wrap>) by one grade as well as a clear-cut reduction in mass effect on CT or MRI assessment with a minimum duration of 4 weeks. There should also be no deterioration in any other neurological symptom or sign and no development of new neurological deficits. Responses had to be documented by two observations at least 4 weeks apart (<xref ref-type="other" rid="bib2">Brock <italic>et al</italic>, 1998</xref>).</p></sec><sec><title>RESULTS</title><p>In general, the combination of TMZ and PCB was well tolerated. Dose level 1 (PCB 50&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> per day given 1&#x02009;h prior to TMZ) from course 2 onwards was well tolerated without any major side effects, as was dose level 2 (PCB 75&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> daily &#x000d7; 5). The only significant toxicity at these two dose levels was lymphocytopenia (<xref rid="tbl4" ref-type="table">Table 4</xref>
 <table-wrap id="tbl4" position="float"><label>Table 4</label><caption><p content-type="table-title">Haematological toxicities. Common toxicity criteria grades 3 and 4</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><tbody valign="top"><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50"><bold>Dose level 1</bold></td><td align="center" valign="top" charoff="50"><bold>Dose level 2</bold></td><td align="center" valign="top" charoff="50"><bold>Dose level 3</bold></td><td align="center" valign="top" charoff="50"><bold>Dose level 4</bold></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;<hr/></td><td align="center" valign="top" charoff="50"><bold>3 patients</bold><hr/></td><td align="center" valign="top" charoff="50"><bold>3 patients</bold><hr/></td><td align="center" valign="top" charoff="50"><bold>16 patients</bold><hr/></td><td align="center" valign="top" charoff="50"><bold>6 patients</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">Anaemia</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Leucopenia</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">1<sup>a</sup></td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Lymphocytopenia</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">3</td><td align="char" valign="top" char="." charoff="50">2<sup>b</sup></td><td align="char" valign="top" char="." charoff="50">1<sup>a</sup></td></tr><tr><td align="left" valign="top" charoff="50">Neutropenia</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">1<sup>a</sup></td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Thrombocytopenia</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">4<sup>c</sup></td><td align="char" valign="top" char="." charoff="50">4</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote1"><label>a</label><p>Temozolomide alone.</p></fn><fn id="tbfnote2"><label>b</label><p>Temozolomide alone, one patient.</p></fn><fn id="tbfnote3"><label>c</label><p>Temozolomide alone, three patients.</p></fn></table-wrap-foot></table-wrap>). At dose level 3 (PCB 100&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> at daily &#x000d7; 5), two patients had falls in their white counts and four patients had thrombocytopenia all on TMZ alone. One patient had thrombocytopenia from the combination of TMZ and PCB. At dose level 4, toxicity was seen and four patients had thrombocytopenia and several patients had moderate-to-severe lethargy and malaise. The recommended dose for future studies is dose level 3. The other toxicities that were seen were skin rashes (two patients) and one patient had hepatitis A infection (<xref rid="tbl5" ref-type="table">Table 5</xref>
 <table-wrap id="tbl5" position="float"><label>Table 5</label><caption><p content-type="table-title">Other toxicities. Common toxicity criteria grades 3 and 4</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><tbody valign="top"><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50"><bold>Dose level 1</bold></td><td align="center" valign="top" charoff="50"><bold>Dose level 2</bold></td><td align="center" valign="top" charoff="50"><bold>Dose level 3</bold></td><td align="center" valign="top" charoff="50"><bold>Dose level 4</bold></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;<hr/></td><td align="center" valign="top" charoff="50"><bold>3 patients</bold><hr/></td><td align="center" valign="top" charoff="50"><bold>3 patients</bold><hr/></td><td align="center" valign="top" charoff="50"><bold>16 patients</bold><hr/></td><td align="center" valign="top" charoff="50"><bold>6 patients</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">Pain&#x0002f;headaches</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50">Stomatitis</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Infection</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">1<sup>a</sup></td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Skin rash</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Raised (ALT) transaminases</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">1<sup>b</sup></td><td align="char" valign="top" char="." charoff="50">1<sup>a</sup></td></tr><tr><td align="left" valign="top" charoff="50">Raised bilirubin</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">1<sup>b</sup></td><td align="char" valign="top" char="." charoff="50">0</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote4"><label>a</label><p>Temozolomide alone.</p></fn><fn id="tbfnote5"><label>b</label><p>Hepatitis A infection, one patient.</p></fn></table-wrap-foot></table-wrap>).</p><p>The responses by tumour grade are shown in <xref rid="tbl6" ref-type="table">Table 6</xref>
 <table-wrap id="tbl6" position="float"><label>Table 6</label><caption><p content-type="table-title">Response to histological grade</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><tbody valign="top"><tr><td align="left" valign="top" charoff="50"><bold>Tumour grade</bold><hr/></td><td align="center" valign="top" charoff="50"><bold>Response &#x00025;</bold><hr/></td><td align="center" valign="top" charoff="50"><bold>Stable disease</bold><hr/></td><td align="center" valign="top" charoff="50"><bold>Progressive disease</bold><hr/></td><td align="center" valign="top" charoff="50"><bold>Total patient no.</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">2</td><td align="char" valign="top" char="." charoff="50">1 (20)</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">3</td><td align="char" valign="top" char="." charoff="50">5</td></tr><tr><td align="left" valign="top" charoff="50">3 (AA)</td><td align="char" valign="top" char="." charoff="50">3 (50)</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">6</td></tr><tr><td align="left" valign="top" charoff="50">4 (GBM)</td><td align="char" valign="top" char="." charoff="50">6 (35)</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">11</td><td align="char" valign="top" char="." charoff="50">17</td></tr><tr><td align="left" valign="top" charoff="50">TOTAL (&#x00025;)</td><td align="char" valign="top" char="." charoff="50">10 (36)</td><td align="center" valign="top" charoff="50">2 (7)</td><td align="center" valign="top" charoff="50">16 (57)</td><td align="char" valign="top" char="." charoff="50">28</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote6"><label/><p>AA&#x0003d;anaplastic astrocytoma, GBM&#x0003d;glioblastoma multiforme.</p></fn></table-wrap-foot></table-wrap>. Responses were seen in all types of glioma, with an overall response rate of 36&#x00025;. <xref rid="tbl7" ref-type="table">Table 7</xref>
 <table-wrap id="tbl7" position="float"><label>Table 7</label><caption><p content-type="table-title">Responses by dose of procarbazine</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><tbody valign="top"><tr><td align="left" valign="top" charoff="50"><bold>Dose level</bold><hr/></td><td align="center" valign="top" charoff="50"><bold>Response (&#x00025;)</bold><hr/></td><td align="center" valign="top" charoff="50"><bold>Stable disease</bold><hr/></td><td align="center" valign="top" charoff="50"><bold>Progressive disease</bold><hr/></td><td align="center" valign="top" charoff="50"><bold>Total patient no.</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">Procarbazine 50&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> &#x000d7; 5</td><td align="char" valign="top" char="." charoff="50">1 (33)</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50">Procarbazine 75&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> &#x000d7; 5</td><td align="char" valign="top" char="." charoff="50">1 (33)</td><td align="char" valign="top" char="." charoff="50">0</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50">Procarbazine 100&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> &#x000d7; 5</td><td align="char" valign="top" char="." charoff="50">5 (31)</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">10</td><td align="char" valign="top" char="." charoff="50">16</td></tr><tr><td align="left" valign="top" charoff="50">Procarbazine 125&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> &#x000d7; 5</td><td align="char" valign="top" char="." charoff="50">3 (50)</td><td align="char" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">6</td></tr><tr><td align="left" valign="top" charoff="50">Total (&#x00025;)</td><td align="char" valign="top" char="." charoff="50">10 (36)</td><td align="char" valign="top" char="." charoff="50">2 (7)</td><td align="char" valign="top" char="." charoff="50">16 (57)</td><td align="char" valign="top" char="." charoff="50">28</td></tr></tbody></table></table-wrap> shows the response by PCB dose and responses were seen at all dose levels. <xref rid="tbl8" ref-type="table">Table 8</xref>
 <table-wrap id="tbl8" position="float"><label>Table 8</label><caption><p content-type="table-title">Response duration</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/></colgroup><tbody valign="top"><tr><td align="left" valign="top" charoff="50"><bold>Procarbazine dose level</bold><hr/></td><td align="center" valign="top" charoff="50"><bold>Months</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">17&#x0002b;</td></tr><tr><td align="left" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">11</td></tr><tr><td align="left" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">6&#x0002b;, 7&#x0002b;, 8&#x0002b;, 13&#x0002b;, 14&#x0002b;</td></tr><tr><td align="left" valign="top" charoff="50">4</td><td align="center" valign="top" charoff="50">2, 5&#x0002b;, 6&#x0002b;</td></tr></tbody></table></table-wrap> shows the duration of responses to 1 September 2001, the duration of responses lasting from 2 to 17&#x0002b; months. <xref ref-type="fig" rid="fig1">Figure 1</xref><fig id="fig1"><label>Figure 1</label><caption><p>Glioma grade II patient transforming to GBM. This MRI shows a patient with grade II glioma, which had transformed to GBM. This is an ongoing response to TMZ and PCB at dose level 3 at 14&#x0002b; months.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="jpeg" xlink:href="89-6601043f1"/></fig> shows a response in a patient receiving treatment at dose level 3.</p></sec><sec><title>DISCUSSION</title><p>Using the criteria of response, we have previously published responses in patients with high-grade gliomas (AA and GBM) to TMZ that are well documented and approximately one in four patients achieves an objective response with clearcut neurological improvement and reduction in the area of enhancement on their MRI scan (<xref ref-type="other" rid="bib2">Brock <italic>et al</italic>, 1998</xref>). A further 25&#x00025; have disease stabilisation in terms of their MRI scans and some neurological improvement when TMZ is given in the dose of 200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> days 1&#x02013;5 schedule repeated at 4 weekly intervals. In the randomised study of TMZ against PCB, the response rate to PCB was lower, the duration of those responses shorter, and the quality of life poorer. However, PCB clearly had modest activity against high-grade gliomas (<xref ref-type="other" rid="bib21">Yung <italic>et al</italic>, 2000</xref>).</p><p>In this study, the combination of TMZ and PCB was generally well tolerated at doses up to dose level 3. At this dose level, there is little difference in terms of side effects between TMZ alone and the combination with PCB. We had intended to extend this cohort to 30 or 40 patients to identify whether or not the combination was superior to TMZ on its own. However, the supply of PCB was interrupted and the study had to be suspended when a total of 16 patients had been entered at dose level 3. Clearly, these results on a small number of patients are preliminary. The clinical impression is that the combination probably is a bit more active than TMZ on its own, and it may be that some of the patients who would otherwise have been classified as having stable disease would have moved into the responding group, suggesting a greater antitumour activity when the two agents are given together.</p></sec><sec><title>CONCLUSION</title><p>TMZ and PCB, when combined at the recommended dose levels, are a reasonably effective and well-tolerated combination in treating patients with relapsed gliomas and tumour activity is seen in low-grade gliomas, AA, and GBM.</p></sec></body><back><ack><p>We are grateful to Schering-Plough Research Institute for providing the temozolomide for this study.</p></ack><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baer</surname><given-names>JC</given-names></name><name><surname>Freeman</surname><given-names>AA</given-names></name><name><surname>Newlands</surname><given-names>ES</given-names></name><name><surname>Watson</surname><given-names>AJ</given-names></name><name><surname>Rafferty</surname><given-names>JA</given-names></name><name><surname>Margison</surname><given-names>GP</given-names></name></person-group><article-title>Depletion of <italic>O</italic><sup>6</sup>-alkylguanine DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells</article-title><source>Br J Cancer</source><year>1993</year><volume>67</volume><fpage>1299</fpage><lpage>1302</lpage><!--PubMed citation query: 'Br J Cancer||67|1299||bib1|'--><pub-id pub-id-type="pmid">8512814</pub-id></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brock</surname><given-names>CS</given-names></name><name><surname>Newlands</surname><given-names>ES</given-names></name><name><surname>Wedge</surname><given-names>SR</given-names></name><name><surname>Bower</surname><given-names>M</given-names></name><name><surname>Colquhorn</surname><given-names>I</given-names></name><name><surname>Roddie</surname><given-names>M</given-names></name><name><surname>Brampton</surname><given-names>M</given-names></name><name><surname>Rusti</surname><given-names>GJ</given-names></name></person-group><article-title>Phase I trial of temozolomide using an extended continuous oral schedule</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><fpage>4363</fpage><lpage>4367</lpage><!--PubMed citation query: 'Cancer Res||58|4363||bib2|'--><pub-id pub-id-type="pmid">9766665</pub-id></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D'Incalci</surname><given-names>M</given-names></name><name><surname>Taverna</surname><given-names>P</given-names></name><name><surname>Erba</surname><given-names>E</given-names></name><name><surname>Filippeschi</surname><given-names>S</given-names></name><name><surname>Potenza</surname><given-names>D</given-names></name><name><surname>Mariani</surname><given-names>L</given-names></name><name><surname>Citti</surname><given-names>L</given-names></name><name><surname>Catapano</surname><given-names>CV</given-names></name></person-group><article-title><italic>O</italic><sup>6</sup>-methylguanine and temozolomide can reverse the resistance to chloroethylnitrosoureas of a mouse L1210 leukaemia</article-title><source>Anticancer Res</source><year>1991</year><volume>11</volume><fpage>115</fpage><lpage>122</lpage><!--PubMed citation query: 'Anticancer Res||11|115||bib3|'--><pub-id pub-id-type="pmid">2018345</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fine</surname><given-names>HA</given-names></name><name><surname>Dear</surname><given-names>KB</given-names></name><name><surname>Loeffler</surname><given-names>JS</given-names></name><name><surname>Black</surname><given-names>PM</given-names></name><name><surname>Canellos</surname><given-names>GP</given-names></name></person-group><article-title>Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults</article-title><source>Cancer</source><year>1993</year><volume>71</volume><fpage>2585</fpage><lpage>2587</lpage><!--PubMed citation query: 'Cancer||71|2585||bib4|'--><pub-id pub-id-type="pmid">8453582</pub-id></citation></ref><ref id="bib5"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Georges</surname><given-names>P</given-names></name><name><surname>Przedborskis</surname><given-names>S</given-names></name><name><surname>Brotchi</surname><given-names>J</given-names></name><name><surname>Chatel</surname><given-names>M</given-names></name><name><surname>Gedovin</surname><given-names>D</given-names></name><name><surname>Hildebrand</surname><given-names>J</given-names></name></person-group><article-title>Effect of HECNU in malignant supratentorial gliomas: a phase II study</article-title><source>J Neuro-oncol</source><year>1988</year><fpage>211</fpage><lpage>219</lpage></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>VA</given-names></name><name><surname>Edwards</surname><given-names>MS</given-names></name><name><surname>Seager</surname><given-names>ML</given-names></name><name><surname>Schimberg</surname><given-names>JP</given-names></name><name><surname>Townsend</surname><given-names>JJ</given-names></name><name><surname>Wilson</surname><given-names>CB</given-names></name></person-group><article-title>Modified procarbazine, CCNU and vincristine brain tumours</article-title><source>Cancer Treat Rep</source><year>1980</year><volume>64</volume><fpage>237</fpage><lpage>241</lpage><!--PubMed citation query: 'Cancer Treat Rep||64|237||bib6|'--><pub-id pub-id-type="pmid">7407756</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>RB</given-names></name><name><surname>Dolan</surname><given-names>ME</given-names></name></person-group><article-title>Effect of temozolomide and dacarbazine on <italic>O</italic><sup>6</sup>-alkylguanine DNA alkytransferase activity and sensitivity of human tumour cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea</article-title><source>Cancer Chemother Pharmacol</source><year>1993</year><volume>32</volume><fpage>59</fpage><lpage>63</lpage><!--PubMed citation query: 'Cancer Chemother Pharmacol||32|59||bib7|'--><pub-id pub-id-type="pmid">8462125</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newlands</surname><given-names>ES</given-names></name><name><surname>Blackledge</surname><given-names>GR</given-names></name><name><surname>Slack</surname><given-names>JA</given-names></name><name><surname>Rustin</surname><given-names>GJ</given-names></name><name><surname>Smith</surname><given-names>DB</given-names></name><name><surname>Stuart</surname><given-names>NS</given-names></name><name><surname>Quartermain</surname><given-names>CP</given-names></name><name><surname>Hoffman</surname><given-names>R</given-names></name><name><surname>Stevens</surname><given-names>MF</given-names></name><name><surname>Brampton</surname><given-names>MH</given-names></name></person-group><article-title>Phase I trial of temozolomide (CCRG 81045; M&#x00026;B 39831)</article-title><source>Br J Cancer</source><year>1992</year><volume>65</volume><fpage>287</fpage><!--PubMed citation query: 'Br J Cancer||65|287||bib8|'--><pub-id pub-id-type="pmid">1739631</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>LA</given-names></name><name><surname>Levin</surname><given-names>VA</given-names></name></person-group><article-title>Does chemotherapy benefit the patient with a central nervous system glioma</article-title><source>Oncology</source><year>1987</year><volume>1</volume><fpage>29</fpage><lpage>36</lpage><!--PubMed citation query: 'Oncology||1|29||bib9|'--></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>SJ</given-names></name><name><surname>Ye</surname><given-names>YW</given-names></name><name><surname>Waber</surname><given-names>PG</given-names></name><name><surname>Shuford</surname><given-names>M</given-names></name><name><surname>Scold</surname><given-names>SC</given-names><suffix>Jr</suffix></name><name><surname>Nisen</surname><given-names>PD</given-names></name></person-group><article-title>p53 mutations, <italic>O</italic><sup>6</sup>-alkylguanine DNA alkytransferase activity and sensitivity to procarbazine in human brain tumours</article-title><source>Cancer</source><year>1995</year><volume>75</volume><fpage>1339</fpage><lpage>1342</lpage><!--PubMed citation query: 'Cancer||75|1339||bib10|'--><pub-id pub-id-type="pmid">7882284</pub-id></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sandberg-Wollheim</surname><given-names>M</given-names></name></person-group><article-title>A randomised study of chemotherapy with procarbazine, vincristine and lomustine with and without radiation therapy for astrocytoma grades 3 and&#x0002f;or 4</article-title><source>Cancer</source><year>1991</year><volume>68</volume><fpage>22</fpage><lpage>29</lpage><italic>et al</italic><!--PubMed citation query: 'Cancer||68|22||bib11|'--><pub-id pub-id-type="pmid">2049748</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schold</surname><given-names>SC</given-names></name></person-group><article-title><italic>O</italic><sup>6</sup>-alkylguanine DNA alkytransferase and sensitivity to procarbazine in human brain tumour xenografts</article-title><source>J Neurosurg</source><year>1989</year><volume>70</volume><fpage>573</fpage><lpage>577</lpage><italic>et al</italic><!--PubMed citation query: 'J Neurosurg||70|573||bib12|'--><pub-id pub-id-type="pmid">2926498</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Souliotis</surname><given-names>VL</given-names></name></person-group><article-title>Accumulation of <italic>O</italic><sup>6</sup>-methylguanine in human blood leukocyte DNA during exposure to procarbazine and its relationships with dose and repair</article-title><source>Cancer Res</source><year>1990</year><volume>50</volume><fpage>2764</fpage><italic>et al</italic><!--PubMed citation query: 'Cancer Res||50|2764||bib13|'--></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>MFG</given-names></name></person-group><article-title>Antitumour activity and pharmacokinetics in mice of 8-carbamoyl-3-(2-chloroethyl) imidazo&#x0005b;5,1,d&#x0005d;-1,2,3,5-tetrazin-4(3&#x02009;H)-one (CCRG 81045; M&#x00026;B 39831) a novel drug with potential as an alternative to dacarbazine</article-title><source>Cancer Res</source><year>1987</year><volume>47</volume><fpage>5846</fpage><italic>et al</italic><!--PubMed citation query: 'Cancer Res||47|5846||bib14|'--><pub-id pub-id-type="pmid">3664486</pub-id></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>MFG</given-names></name></person-group><article-title>Antitumour imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl) imidazo&#x0005b;5,1,d&#x0005d;-1,2,3,5-tetrazin-4(3H)-one, a novel broad spectrum antitumour agent</article-title><source>J Med Chem</source><year>1984</year><volume>27</volume><fpage>196</fpage><italic>et al</italic><!--PubMed citation query: 'J Med Chem||27|196||bib15|'--><pub-id pub-id-type="pmid">6694168</pub-id></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>DJ</given-names></name></person-group><article-title>The role of chemotherapy in the treatment of gliomas in adults</article-title><source>Cancer Treat Rev</source><year>1989</year><volume>16</volume><fpage>129</fpage><lpage>160</lpage><!--PubMed citation query: 'Cancer Treat Rev||16|129||bib16|'--></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tisdale</surname><given-names>MJ</given-names></name></person-group><article-title>Antitumour imidazotetrazines. XV. Role of guanine <italic>O</italic><sup>6</sup>-alkylation in the mechanism of cytotoxicity of imidazotetrazines</article-title><source>Biochem Pharmacol</source><year>1987</year><volume>36</volume><fpage>457</fpage><lpage>462</lpage><!--PubMed citation query: 'Biochem Pharmacol||36|457||bib17|'--><pub-id pub-id-type="pmid">3470008</pub-id></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valvanis</surname><given-names>C</given-names></name></person-group><article-title>Differential effects of procarbazine and methylnitrosoureas on the accumulation of <italic>O</italic><sup>6</sup>-methylguanine and the depletion and recovery of <italic>O</italic><sup>6</sup>-alkylguanine DNA alkytransferase in rat tissues</article-title><source>Carcinogenesis</source><year>1994</year><volume>15</volume><fpage>1681</fpage><lpage>1688</lpage><italic>et al</italic><!--PubMed citation query: 'Carcinogenesis||15|1681||bib18|'--><pub-id pub-id-type="pmid">7519972</pub-id></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>ME</given-names></name></person-group><article-title>Evaluation of BCNU and&#x0002f;or radiotherapy in the treatment of anaplastic gliomas: a co-operative clinical trial</article-title><source>J Neurosurg</source><year>1978</year><volume>49</volume><fpage>333</fpage><lpage>343</lpage><italic>et al</italic><!--PubMed citation query: 'J Neurosurg||49|333||bib19|'--><pub-id pub-id-type="pmid">355604</pub-id></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wedge</surname><given-names>SR</given-names></name></person-group><article-title>Potentiation of temozolomide and BCNU cytotoxicity by <italic>O</italic><sup>6</sup>-benzylguanine: a comparative study <italic>in vitro</italic></article-title><source>Br J Cancer</source><year>1996</year><volume>73</volume><fpage>482</fpage><lpage>490</lpage><italic>et al</italic><!--PubMed citation query: 'Br J Cancer||73|482||bib20|'--><pub-id pub-id-type="pmid">8595163</pub-id></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yung</surname><given-names>WKA</given-names></name></person-group><article-title>A Phase II study of temozolomide <italic>vs</italic>. procarbazine in patients with glioblastoma multiforme at first relapse</article-title><source>Br J Cancer</source><year>2000</year><volume>83</volume><fpage>588</fpage><lpage>593</lpage><italic>et al</italic><!--PubMed citation query: 'Br J Cancer||83|588||bib21|'--><pub-id pub-id-type="pmid">10944597</pub-id></citation></ref></ref-list></back></article>


